Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 379

The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.

Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel

Open access
de Witte, Theo, Bowen, David, Robin, Marie, Malcovati, Luca, Niederwieser, Dietger, Yakoub-Agha, Ibrahim, Mufti, Ghulam J., Fenaux, Pierre, Sanz, Guillermo, Martino, Rodrigo, Alessandrino, Emilio Paolo, Onida, Francesco, Symeonidis, Argiris, Passweg, Jakob, Kobbe, Guido, Ganser, Arnold, Platzbecker, Uwe, Finke, Jürgen, van Gelder, Michel, van de Loosdrecht, Arjan A., Ljungman, Per, Stauder, Reinhard, Volin, Liisa, Deeg, H. Joachim, Cutler, Corey, Saber, Wael, Champlin, Richard, Giralt, Sergio, Anasetti, Claudio, Kröger, Nicolaus·2017·Blood

Abstract

An international expert panel, active within the European Society for Blood and Marrow Transplantation, European LeukemiaNet, Blood and Marrow Transplant Clinical Trial Group, and the International Myelodysplastic Syndromes Foundation developed recommendations for allogeneic hematopoietic stem cell transplantation (HSCT) in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). Disease risks scored according to the revised International Prognostic Scoring System (IPSS-R) and presence of comorbidity graded according to the HCT Comorbidity Index (HCT-CI) were recognized as relevant clinical variables for HSCT eligibility. Fit patients with higher-risk IPSS-R and those with lower-risk IPSS-R with poor-risk genetic features, profound cytopenias, and high transfusion burden are candidates for HSCT. Patients with a very high MDS transplantation risk score, based on combination of advanced age, high HCT-CI, very poor-risk cytogenetic and molecular features, and high IPSS-R score have a low chance of cure with standard HSCT and consideration should be given to treating these patients in investigational studies. Cytoreductive therapy prior to HSCT is advised for patients with ≥10% bone marrow myeloblasts. Evidence from prospective randomized clinical trials does not provide support for specific recommendations on the optimal high intensity conditioning regimen. For patients with contraindications to high-intensity preparative regimens, reduced intensity conditioning should be considered. Optimal timing of HSCT requires careful evaluation of the available effective nontransplant strategies. Prophylactic donor lymphocyte infusion (DLI) strategies are recommended in patients at high risk of relapse after HSCT. Immune modulation by DLI strategies or second HSCT is advised if relapse occurs beyond 6 months after HSCT.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2016-06-724500

Cites

100 of 100 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 100 references

Cited by

See all 379

Metadata

Authors
de Witte, T., Bowen, D., Robin, M., Malcovati, L., Niederwieser, D., Yakoub-Agha, I., Mufti, G. J., Fenaux, P., Sanz, G., Martino, R., Alessandrino, E. P., Onida, F., Symeonidis, A., Passweg, J., Kobbe, G., Ganser, A., Platzbecker, U., Finke, J., van Gelder, M., van de Loosdrecht, A. A., Ljungman, P., Stauder, R., Volin, L., Deeg, H. J., Cutler, C., Saber, W., Champlin, R., Giralt, S., Anasetti, C., & Kröger, N.
Venue
Blood
Published
2017-03-30
Volume
129
Issue
13
Pages
1753-1762
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2575545223
Cited by
379
References
100
FWCI
24.61
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. https://app.cochat.ai/papers/10.1182/blood-2016-06-724500
The paper
de Witte, T., Bowen, D., Robin, M., Malcovati, L., Niederwieser, D., Yakoub-Agha, I., Mufti, G. J., Fenaux, P., Sanz, G., Martino, R., Alessandrino, E. P., Onida, F., Symeonidis, A., Passweg, J., Kobbe, G., Ganser, A., Platzbecker, U., Finke, J., van Gelder, M., . . . Kröger, N. (2017). Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood. https://doi.org/10.1182/blood-2016-06-724500

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.